⚠ Eighty-Four Percent Recurring Is Also Eighty-Four Percent ExposedHigh threat
Intuitive Surgical (ISRG) — threat to the moat
Recurring is not contracted: nothing here obliges a hospital to generate volume.
The recurring share is usually read as a quality metric, and for most of Intuitive's history it has been one. It is also a statement about what the revenue is a function of, and the function is procedure volume.
That matters because of what the procedures are. The 10-K states plainly that "more than half of da Vinci procedures performed are for benign conditions", and that "these benign procedures and other short-term elective procedures tend to be more seasonal than cancer procedures and surgeries for other life-threatening conditions"1. In other words, the majority of the volume can be moved, and patients move it — the filing notes that in the United States benign volumes are "typically seasonally higher in the fourth quarter when more patients have met annual deductibles and lower in the first quarter when deductibles are reset."
A company with 84% recurring revenue and a contracted subscription would be insulated from that. Intuitive has 84% recurring revenue and no contract: instruments are bought when a case is done, service scales with a base that keeps running either way, and usage-based leases bill per procedure. Nothing here obliges a hospital to generate volume.
2026 demonstrated the difference. Deferrable benign categories — hernia repair, cholecystectomy — softened from the first quarter, while non-deferrable categories did not show the same pattern2, and United States procedure growth fell from 14% to 12% between quarters3.
The falsifier is the divergence itself. If deferrable and non-deferrable procedure growth converge again, the softness was a coverage shock working through. If the gap persists for four quarters, the recurring revenue is more cyclical than a 84% figure implies, and it should not carry a subscription multiple.
- ReportedThe 10-K states plainly that "more than half of da Vinci procedures performed are for benign conditions", and that "these benign procedures and other short-term elective procedures tend to be more seasonal than cancer procedures and...Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedDeferrable benign categories — hernia repair, cholecystectomy — softened from the first quarter, while non-deferrable categories did not show the same pattern, and United States procedure growth fell from 14% to 12% between quarters.Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
- ReportedDeferrable benign categories — hernia repair, cholecystectomy — softened from the first quarter, while non-deferrable categories did not show the same pattern, and United States procedure growth fell from 14% to 12% between quarters.Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗